Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milvexian. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 known ✓ | P03951 | 20/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 8/20 | 1.00 |
| ▸ | F2 | P00734 | 1/20 | 1.00 |
| ▸ | PLG | P00747 | 1/20 | 1.00 |
| ▸ | PLAU | P00749 | 1/20 | 1.00 |
| ▸ | PLAT | P00750 | 1/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 1/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 1/20 | 1.00 |
| ▸ | F7 | P08709 | 1/20 | 1.00 |
| ▸ | CTRB1 | P17538 | 1/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 1/20 | 1.00 |
| ▸ | CTRL | P40313 | 1/20 | 1.00 |
| ▸ | CTRB2 | Q6GPI1 | 1/20 | 1.00 |
| ▸ | CTRC | Q99895 | 1/20 | 1.00 |
| ▸ | KLK1 | P06870 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milvexian SCHEMBL16982996 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982794 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29491830 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29392086 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982989 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16982998 | 1.00 | F11 (1.00) | F11KLKB1F2PLGPLAU | |
| SCHEMBL17661921 | 0.96 | F11 (0.92) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL16972161 | 0.95 | F11 (0.91) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29491750 | 0.95 | F11 (0.91) | F11KLKB1F2PLGPLAU | |
| Milvexian SCHEMBL29491953 | 0.95 | F11 (0.91) | F11KLKB1F2PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4188431-A1 | COMBINATION THERAPY FOR CANCER | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2022026398-A1 | COMBINATION THERAPY FOR CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-03 | — | — | WO | claimed |
| US-20260042761-A1 | ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-12 | — | — | US | disclosed |
| US-20260034130-A1 | USE OF MILVEXIAN FOR TREATING OR PREVENTING ISCHEMIC STROKE | BRISTOL MYERS SQUIBB CO (US) | 2026-02-05 | — | — | US | disclosed |
| US-12509461-B2 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-30 | — | — | US | disclosed |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-09-30 | — | — | US | disclosed |
| WO-2025126240-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2025-06-19 | — | — | WO | disclosed |
| US-20240173310-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2024-05-30 | — | — | US | disclosed |
| EP-4304561-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5- DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | Bayer Aktiengesellschaft (DE) | 2024-01-17 | — | — | EP | disclosed |
| CN-117337170-A | Comprises (4S) -2 4 -chloro-4-ethyl-7 3 -fluoro-3 5 -methoxy-3 2 5-dioxo-1 4 - (trifluoromethyl) -3 2 H-6-aza-3 (4, 1) -pyridine-1 (1) - [1,2,3]Triazole-2 (1, 2), 7 (1) -diphenyl heptatomato-7 4 Pharmaceutical dosage form of formamide | 拜耳公司 | 2024-01-02 | — | — | CN | disclosed |
| EP-4286372-A2 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3828186-B1 | PYRIMIDINONES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4188431-A1 | COMBINATION THERAPY FOR CANCER | The Board Of Trustees Of The Leland Stanford Junior University (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230151010-A1 | CRYSTALLINE FORMS OF (9R, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0 2·6] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| EP-4132930-A1 | CRYSTALLINE FORMS OF (9, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE | Bristol-Myers Squibb Company (US) | 2023-02-15 | — | — | EP | disclosed |
| WO-2022189278-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5- DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)- DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 2022-09-15 | — | — | WO | disclosed |
| US-20220144835-A1 | ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-12 | — | — | US | disclosed |
| EP-3988549-A1 | MACROCYCLES WITH HETEROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2022026398-A1 | COMBINATION THERAPY FOR CANCER | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144835-A1 | ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONS | SLCO1B1, F12, NPC1L1 | F11 18/4885KLKB1 290/4885F2 25/4885 |
| US-12509461-B2 | Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations | F10, F12, F2 | F11 8/4885KLKB1 832/4885F2 3/4885 |
| US-20260034130-A1 | USE OF MILVEXIAN FOR TREATING OR PREVENTING ISCHEMIC STROKE | TIMP3, PLAT, MMP13 | F11 8/4885KLKB1 1028/4885F2 65/4885 |
| US-12428421-B2 | Pyrimidinones as factor XIA inhibitors | TFPI, TFPI2, F2 | F11 4/4885KLKB1 7/4885F2 3/4885 |
| US-20260042761-A1 | ENHANCED PERFORMANCE OF AMORPHOUS SOLID AND SOLUBILIZED FORMULATIONS FOR ACHIEVING THERAPEUTIC PLASMA CONCENTRATIONS | F12, F2, TFPI | F11 5/4885KLKB1 829/4885F2 2/4885 |
| US-20240173310-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING (4S)-24-CHLORO-4-ETHYL-73-FLUORO-35-METHOXY-32,5-DIOXO-14-(TRIFLUOROMETHYL)-32H-6-AZA-3(4,1)-PYRIDINA-1(1)-[1,2,3]TRIAZOLA-2(1,2),7(1)-DIBENZENAHEPTAPHANE-74-CARBOXAMIDE | CYP4F8, CYP4F2, CYP2F1 | F11 539/4885KLKB1 2721/4885F2 26/4885 |
| US-20230151010-A1 | CRYSTALLINE FORMS OF (9R, 135S)-13- {4-[5-CHLORO-2-(4-CHLORO-1H,2,3- TRIAZOL- 1 -YL)PHENYL] -6-OXO- 1,6-DIHYDROPYRIMIDIN- 1-YL}-3-(DIFLUOROMETHYL)-9-METHYL-3,4,7,15- TETRAAZATRICYCLO [ 12.3.1.0 2·6] OCTADECA- 1(18), 2(6), 4, 14, 16-PENTAEN-8-ONE | CASP9, TMEM14C, CCT8 | F11 244/4885KLKB1 2903/4885F2 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.